Long-term efficacy and safety of ocrelizumab in treatment-naive patients with early relapsing multiple sclerosis: 7-year data from the OPERA open-label extension trials

被引：0
|
作者：
Cerqueira, J. [1 ]
Berthele, A. [2 ]
Cree, B. [3 ]
Filippi, M. [4 ,5 ,6 ,7 ,8 ]
Pardo, G. [9 ]
Pearson, O. [10 ]
Trabloulsee, A. [11 ]
Ziemssen, T. [12 ]
Vollmer, T. [13 ]
Bernasconi, C. [14 ]
Mandel, C. [15 ]
Overell, J. [14 ]
Havrdova, E. [16 ,17 ,18 ]
机构：
[1] Univ Minho, Life & Hlth Sci Res Inst, Sch Med, Braga, Portugal
[2] Tech Univ Munich, Sch Med, Dept Neurol, Munich, Germany
[3] Univ Calif San Francisco, UCSF Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA
[4] IRCCS San Raffaele Sci Inst, Div Neurosci, Neuroimaging Res Unit, Milan, Italy
[5] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy
[6] IRCCS San Raffaele Sci Inst, Neurorehabilitat Unit, Milan, Italy
[7] IRCCS San Raffaele Sci Inst, Neurophysiol Serv, Milan, Italy
[8] Univ Vita Salute San Raffaele, Milan, Italy
[9] Oklahoma Med Res Fdn, Multiple Sclerosis Ctr Excellence, Oklahoma City, OK USA
[10] Morriston Hosp, Dept Neurol, Swansea, W Glam, Wales
[11] Univ British Columbia, Dept Neurol, Vancouver, BC, Canada
[12] Tech Univ Dresden, Univ Clin Carl Gustav Carus, Dept Neurol, Ctr Clin Neurosci, Dresden, Germany
[13] Univ Colorado Denver, Dept Neurol, Rocky Mt Multiple Sclerosis Ctr, Anschutz Med Campus, Denver, CO USA
[14] F Hoffmann Roche Ltd, Basel, Switzerland
[15] Genentech Inc, San Francisco, CA USA
[16] Gen Univ Hosp, Prague, Czech Republic
[17] Charles Univ Prague, Dept Neurol, Prague, Czech Republic
[18] Charles Univ Prague, Ctr Clin Neurosci, Prague, Czech Republic
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P723
引用
收藏
页码：634 / 635
页数：2
相关论文
共 50 条
  • [21] Open-label Phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS
    Kuhelj, R.
    Deol-Bhullar, G.
    Garas, M.
    Chin, P.
    Hauser, S.
    Montalban, X.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 200 - 200
  • [22] Long-term open-label treatment with Sativex® in patients with multiple sclerosis
    Constantinescu, C. S.
    Sarantis, N.
    MULTIPLE SCLEROSIS, 2006, 12 : S111 - S111
  • [23] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
  • [24] Long-term effect of ocrelizumab on brain volume and lesion activity outcomes in patients with relapsing multiple sclerosis: Analysis of 10-year data from the OPERA trials
    Granziera, Cristina
    Kolind, Shannon
    Traboulsee, Anthony
    Hauser, Stephen
    Bonati, Ulrike
    Wang, Qing
    von Buren, Gisele
    Clayton, David
    Craveiro, Licinio
    Arnold, Douglas L.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 89 - 90
  • [25] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
    Cree, Bruce A. C.
    Selmaj, Krzysztof W.
    Steinman, Lawrence
    Comi, Giancarlo
    Bar-Or, Amit
    Arnold, Douglas L.
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva K.
    Sheffield, James K.
    Minton, Neil
    Cheng, Chun-Yen
    Silva, Diego
    Kappos, Ludwig
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1944 - 1962
  • [26] Design of a multicentre, open-label extension study to evaluate the long-term safety, immunogenicity, anti efficacy of natalizumab in patients with multiple sclerosis
    O'Connor, P
    Toal, M
    Wilmer-Hulme, A
    Yang, M
    Panzara, M
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S261 - S261
  • [27] Long-term safety and efficacy of pregabalin as treatment of painful diabetic neuropathy: findings from 7 open-label extension studies
    Murphy, K.
    Emir, B.
    DIABETOLOGIA, 2008, 51 : S503 - S503
  • [28] Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial.
    Becker, Michael A.
    Baraf, Herbert S. B.
    Yood, Robert A.
    Dillon, Aileen M.
    Vazquez-Mellado, Janitzia
    Ottery, Faith D.
    Khanna, Dinesh
    Sundy, John S.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S69 - S70
  • [29] Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
    Cree, B. A.
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Cheng, C.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 85 - 86
  • [30] Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study
    Miller, Aaron E.
    Olsson, Tomas P.
    Wolinsky, Jerry S.
    Comi, Giancarlo
    Kappos, Ludwig
    Hu, Xueqiang
    Xu, Xianhao
    Lublin, Alex L.
    Truffinet, Philippe
    Chavin, Jeffrey
    Delhay, Jean-Luc
    Benamor, Myriam
    Purvis, Annie
    Freedman, Mark S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
12345